The ABC's of Carcinoid and Neuroendocrine Tumors

Three of the world’s leading carcinoid and NET cancer specialists – Dr. Richard R.P. Warner, Dr. Edward M. Wolin, and Dr. Eugene A. Woltering  – talk about the advice they offer their patients, the advances they have seen during their careers, and what they anticipate will be available for NET patients in the future. (Click on the words YouTube in the bottom right of the video to see it in a larger size).

The Latest News

Carcinoid Syndrome Impact Survey Results to Be Presented During September 21 Webcast: Registration is Now Open

Members of the carcinoid and neuroendocrine tumor community are invited to be the first to hear the results of the Carcinoid Syndrome Impact Survey that was conducted this summer.  A Webcast about the survey results will be presented on Wednesday, September 21, 2016 from 12 noon to 1:30 pm, Eastern Time. Space is limited so please register today.  Read more

Stanford Health Care in California Launches Neuroendocrine Tumor Multidisciplinary Program

A new multidisciplinary Neuroendocrine Cancer center at Stanford Health Care in California has been established to improve the standard of care for NET patients and to advance the study of these rare diseases. Pamela Kunz, MD, is the Medical Director of the NET program. Read more

Co-Medical Director Named at Carcinoid Cancer Foundation

Edward M. Wolin, MD, an internationally renowned neuroendocrine cancer specialist and medical oncologist, has been named Co-Medical Director and Board member of the Carcinoid Cancer Foundation (CCF) in White Plains, New York.  Dr. Wolin is Director of the Neuroendocrine Tumor Program at Montefiore Einstein Center for Cancer Care, a premier cancer center in New York City. Read more

FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors

Breaking news on June 1, 2016 from the U.S. Food and Drug Administration! The FDA has approved NETSPOT, “the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging.”   Read more from the FDA and Read more from Advanced Acclerator Applications

FDA Priority Review of Lexicon’s New Drug Application for Telotristat Etiprate Treatment for Carcinoid Syndrome

Lexicon Pharmaceuticals announced on May 31, 2016 that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for telotristat etiprate, an oral drug for the treatment of CARCINOID SYNDROME. “The FDA has granted a Priority Review of the NDA filing and set a Prescription Drug User Fee Act (“PDUFA”) target action date of November 30, 2016.” Read more

One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration during the week of April 25, 2016, a decision from the FDA is expected by early 2017.  Additionally, an Expanded Access Program (EAP) in the United States for the investigational product, Lutathera, is expected to begin in about 2 months at 2-5 institutions. Read more